logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Sangamo: In Vivo Editing of the Gene Behind Hunter Syndrome

Yes, it is Sangamo’s (SGMO) zinc finger nuclease (ZFN) gene-editing technology, which for the first time in history enabled a patient to receive a treatment to edit the DNA of his cells directly inside the body. That was the news...

Read More

November 15, 2017

0

Amgen and UCB product for bone fracture in susceptible postmenopausal women. What about the Market's deep dips?

Another reason was found to hit the market when the economy is good and sustained and expected to be of a long duration. Of a short duration are the causes presented as economy killers. They are almost all related to...

Read More

December 6, 2018

0

There are no reasons for the Market's tumbling. The value of the Biotech Revolution.

Today, the market took another beating as a result of either an intentional or an unintentional lack of clearance by professionals in describing correctly the standing of employment and other current economic realities. They pinpointed irrelevant reasons in an effort to...

Read More

December 7, 2018

0

Searching for a New Promising Development-Stage Biotech Firm We Found and Picked This One

Krystal Biotech Krystal Biotech ( KRYS ) is  a gene therapy firm focused on developing topical intradermal therapeutics for rare dermatological diseases. It developed its a gene therapy product KB103 for the treatment of the broad Dystrophic epidermolysis bullosa ( DEB)...

Read More

June 25, 2019

0

Atossa Genetics Has Promising News

Atossa Genetics Promising News for Endoxifen Atossa Genetics ( ATOS )   has promising news from a Phase 2 trial of its topical Endoxifen for mammographic breast density ( MBD ) reduction.     Preliminary analysis from a recently completed Phase...

Read More

June 27, 2019

0

Marinus Pharmaceuticals: A successful treatment for Postpartum Depression

Marinus Pharmaceuticals (MRNS) announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV),  the Magnolia Study, and oral dose, the Amaryllis Study, in women with postpartum depression (PPD) . Based on the positive results, the company is...

Read More

December 10, 2018

0

Could DelMar Pharmaceuticals' Drug VAL-083 ($1 Stock Price) Defeat Glioblastoma Multiforme?

DelMar Pharmaceuticals (DMPI) -- A biopharmaceutical company focused on the development of cancer therapies provided an overview of three scientific posters presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) held on November 16-19, 2017...

Read More

November 22, 2017

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

In Spite of Negative Indirect Attempts to Downgrade Portola, It Remains One of Our Favorites

On Nov. 21, 2017, Portola Pharmaceuticals (PTLA) announced that the U.S. Food and Drug Administration (FDA) has informed it that it will respond to the Prior Approval Supplement (PAS) request to change the current manufacturing release specification within the standard 60-day extension...

Read More

November 24, 2017

0

Amgen, Rhythm Pharmaceuticals and an important story to know

Amgen Higher Dividends For those who invest in top-tier biotech firms for dividend payments, in addition to the firms’ continued growth, Amgen (AMGN) announced last Friday that its Board of Directors declared a  $1.45 per share dividend for the first quarter...

Read More

December 12, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 63
  • 64
  • 65
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy